JAGX
Jaguar Health·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Stock Price Surged Significantly
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About JAGX
Jaguar Health, Inc.
A commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for GI distress, including chronic, and debilitating diarrhea
Healthcare Equipment and Supplies
06/06/2013
05/13/2015
NASDAQ Stock Exchange
49
12-31
Common stock
200 Pine Street, Suite 400, San Francisco, California 94104
--
Jaguar Health, Inc., was incorporated in Delaware on June 6, 2013. The Company is a commercial-stage pharmaceutical company focused on the development of novel patented prescription medicines sustainably extracted from plants in rainforest regions for humans and animals with gastrointestinal (" GI ") diseases.
Earnings Call
Q1/2025
Estimate EPS-10.82
Actual EPS-16.7
Estimate Revenue2.82M
Actual Revenue2.21M
Jaguar Health's Q1 2025 Earnings Call: Key Contradictions in Revenue Growth, Prescription Trends, and Regulatory Strategy
May 16,2025 05:41
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
JAGX has released its 2025 Q2 earnings. EPS was reported at -10.26, versus the expected -7.13, missing expectations. The chart below visualizes how JAGX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
JAGX has released its 2025 Q3 earnings report, with revenue of 3.08M, reflecting a YoY change of -0.80%, and net profit of -9.65M, showing a YoY change of 3.72%. The Sankey diagram below clearly presents JAGX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
